Form 4: Harmony Biosciences Director R. Mark Graf Acquires Stock Options

Director R. Mark Graf acquired 14,522 stock options in Harmony Biosciences Holdings, Inc.

Summary

• R. Mark Graf, a director of Harmony Biosciences Holdings, Inc., reported a transaction on May 15, 2025.
• Graf acquired 14,522 stock options with an exercise price of $34.23.
• These options vest fully on the earlier of May 15, 2026, or the date of the next annual meeting following the grant date, contingent upon continued service.
• Following the transaction, Graf directly owns 14,522 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option acquisition by a director. While insider buying can be seen as positive, it's not necessarily a strong indicator of future performance.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting of the stock options is contingent upon continued service, suggesting an expectation of continued involvement by the director.

Industry Context

This is a standard SEC Form 4 filing, reflecting insider transactions in a publicly traded company. Such filings are common and provide transparency into the actions of company insiders.

Stakeholder Impact

• The transaction provides transparency to shareholders regarding insider activity.

Key Dates

Keywords

stock options, Form 4, Harmony Biosciences, HRMY, director, insider trading, R. Mark Graf